Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;25(2):128-140.
doi: 10.1080/13697137.2021.1948006. Epub 2021 Aug 4.

Effect of menopausal symptom treatment options on palpitations: a systematic review

Y Sheng  1 , J S Carpenter  1 , C D Elomba  1 , J S Alwine  1 , M Yue  2 , C X Chen  1 , J E Tisdale  2   3
Affiliations

Effect of menopausal symptom treatment options on palpitations: a systematic review

Y Sheng et al. Climacteric. 2022 Apr.

Abstract

This systematic review provides an overview of the effects of menopausal symptom treatment options on palpitations, defined as feelings of missed or exaggerated heart beats, reported by perimenopausal and postmenopausal women. Guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searches were conducted in PubMed, CINAHL and PsycINFO to identify articles meeting pre-specified inclusion criteria. Of 670 unique articles identified, 37 were included in the review. Treatments included drug therapies and non-drug therapies. Palpitations were studied as an outcome in 89% of articles and as an adverse effect in 11%. Articles provided mostly level II/III evidence due to their design and/or small sample sizes. Based on available evidence, no therapies can be fully recommended for clinical practice. Only some hormonal agents (e.g. estradiol) can be recommended with caution based on some positive evidence for reducing palpitation prevalence or severity. However, other drug therapies (e.g. moxonidine, atenolol), dietary supplementary treatments (e.g. isoflavones, Rheum rhaponticum, sage), cognitive-behavioral intervention and auricular acupressure cannot be recommended given the existing evidence. Additional well-designed randomized controlled treatment trials focusing on palpitations during the menopause transition as an inclusion criteria and outcome are needed to advance the field.

Keywords: Menopausal therapy; menopausal symptoms; menopause; palpitations; perimenopause; postmenopause; systematic review.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram depicting disposition of the articles.
See this image and copyright information in PMC

References

    1. North American Menopause Society. Menopause Practice: A Clinician's Guide 6th ed. Mayfield Heights, OH: North American: Menopause Society; 2019.
    1. Islam RM, Bell RJ, Billah B, et al. Prevalence and severity of vasomotor symptoms and joint pain in women at midlife in Bangladesh: a population-based survey. Menopause 2016;23(7):731–739. - PubMed
    1. Islam RM, Bell RJ, Rizvi F, et al. Vasomotor symptoms in women in Asia appear comparable with women in Western countries: a systematic review. Menopause 2017;24(11):1313–1322. - PubMed
    1. Minkin MJ, Reiter S, Maamari R. Prevalence of postmenopausal symptoms in North America and Europe. Menopause 2015;22(11):1231–1238. - PubMed
    1. Sriprasert I, Pantasri T, Piyamongkol W, et al. An International Menopause Society study of vasomotor symptoms in Bangkok and Chiang Mai, Thailand. Climacteric 2017;20(2):171–177. - PubMed

Publication types